Goldman Sachs’s ACELYRIN SLRN Stock Holding History

Goldman Sachs’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-351,407	Closed	-$868K	–	6390
2025 Q1	$868K	Sell	351,407 -218,503	-38%	-$520K	﹤0.01%	4799
2024 Q4	$1.79M	Buy	569,910 +47,988	+9%	+$232K	﹤0.01%	4379
2024 Q3	$2.57M	Sell	521,922 -277,710	-35%	-$1.43M	﹤0.01%	3927
2024 Q2	$3.53M	Buy	799,632 +43,732	+6%	+$205K	﹤0.01%	3481
2024 Q1	$5.1M	Sell	755,900 -363,011	-32%	-$2.76M	﹤0.01%	3071
2023 Q4	$8.35M	Sell	1,118,911 -660,914	-37%	-$5.64M	﹤0.01%	2698
2023 Q3	$18.1M	Buy	1,779,825 +1,469,827	+474%	+$31.2M	﹤0.01%	1898
2023 Q2	$6.48M	Buy	+309,998	New	+$6.34M	﹤0.01%	2873

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's SLRN Position: Q2 2025 in Review

Goldman Sachs sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 351,407 shares — an estimated $868K sold.

Goldman Sachs first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $18.1M in Q3 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Goldman Sachs reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Goldman Sachs sold 351,407 ACELYRIN shares in Q2 2025, an estimated $868K.
Goldman Sachs first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
Goldman Sachs's ACELYRIN position peaked at $18.1M in Q3 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.